CTLA4 and metastatic neoplasm: Clinical significance of these approaches can further be tested both in-vitro and in-vivo in combination with already established immunotherapeutic agents, such as PD1/PDL1/CTLA4 blocking antibodies, commonly used for the treatment of metastatic disease.